CA2665723A1 - Procede de detection de la dimension d'un acide nucleique - Google Patents
Procede de detection de la dimension d'un acide nucleique Download PDFInfo
- Publication number
- CA2665723A1 CA2665723A1 CA002665723A CA2665723A CA2665723A1 CA 2665723 A1 CA2665723 A1 CA 2665723A1 CA 002665723 A CA002665723 A CA 002665723A CA 2665723 A CA2665723 A CA 2665723A CA 2665723 A1 CA2665723 A1 CA 2665723A1
- Authority
- CA
- Canada
- Prior art keywords
- tandem repeat
- segment
- nucleic acid
- fraction
- repeats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 260
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 238
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 238
- 238000001514 detection method Methods 0.000 title claims description 42
- 238000000034 method Methods 0.000 claims abstract description 205
- 239000003550 marker Substances 0.000 claims abstract description 151
- 239000012634 fragment Substances 0.000 claims description 202
- 239000000523 sample Substances 0.000 claims description 148
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 130
- 230000003321 amplification Effects 0.000 claims description 129
- 230000035772 mutation Effects 0.000 claims description 101
- 238000003752 polymerase chain reaction Methods 0.000 claims description 98
- 108700028369 Alleles Proteins 0.000 claims description 96
- 108091008146 restriction endonucleases Proteins 0.000 claims description 79
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 239000002773 nucleotide Substances 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 101150082209 Fmr1 gene Proteins 0.000 claims description 34
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 31
- 238000011144 upstream manufacturing Methods 0.000 claims description 29
- 238000000926 separation method Methods 0.000 claims description 26
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims description 25
- 238000005251 capillar electrophoresis Methods 0.000 claims description 21
- 238000001962 electrophoresis Methods 0.000 claims description 16
- 238000004513 sizing Methods 0.000 claims description 16
- 210000001766 X chromosome Anatomy 0.000 claims description 15
- 108010007570 Amelogenin Proteins 0.000 claims description 14
- 210000002593 Y chromosome Anatomy 0.000 claims description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 12
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 101000861386 Homo sapiens Frataxin, mitochondrial Proteins 0.000 claims description 9
- 229940104302 cytosine Drugs 0.000 claims description 6
- 102000007371 Ataxin-3 Human genes 0.000 claims description 4
- 108010032947 Ataxin-3 Proteins 0.000 claims description 4
- 102100027525 Frataxin, mitochondrial Human genes 0.000 claims description 4
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 102000002785 Ataxin-10 Human genes 0.000 claims description 3
- 108010043914 Ataxin-10 Proteins 0.000 claims description 3
- 102000007368 Ataxin-7 Human genes 0.000 claims description 3
- 108010032953 Ataxin-7 Proteins 0.000 claims description 3
- 102000007370 Ataxin2 Human genes 0.000 claims description 3
- 108010032951 Ataxin2 Proteins 0.000 claims description 3
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 claims description 3
- 102100026891 Cystatin-B Human genes 0.000 claims description 3
- 101000710837 Homo sapiens CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 claims description 3
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 claims description 3
- 101000891654 Homo sapiens TATA-box-binding protein Proteins 0.000 claims description 3
- 101000935117 Homo sapiens Voltage-dependent P/Q-type calcium channel subunit alpha-1A Proteins 0.000 claims description 3
- 102100040296 TATA-box-binding protein Human genes 0.000 claims description 3
- 108010032963 Ataxin-1 Proteins 0.000 claims description 2
- 208000033255 Progressive myoclonic epilepsy type 1 Diseases 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 102100022437 Myotonin-protein kinase Human genes 0.000 claims 2
- 102000007372 Ataxin-1 Human genes 0.000 claims 1
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 claims 1
- 102100040227 Homeobox protein Hox-D13 Human genes 0.000 claims 1
- 101001037168 Homo sapiens Homeobox protein Hox-D13 Proteins 0.000 claims 1
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 claims 1
- 101000701517 Homo sapiens Putative protein ATXN8OS Proteins 0.000 claims 1
- 101000915806 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Proteins 0.000 claims 1
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 claims 1
- 102100030469 Putative protein ATXN8OS Human genes 0.000 claims 1
- 102100029014 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Human genes 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 102100025330 Voltage-dependent P/Q-type calcium channel subunit alpha-1A Human genes 0.000 claims 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 149
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 33
- 238000013467 fragmentation Methods 0.000 abstract description 29
- 238000006062 fragmentation reaction Methods 0.000 abstract description 29
- 201000010099 disease Diseases 0.000 abstract description 27
- 238000005194 fractionation Methods 0.000 abstract description 18
- 239000000969 carrier Substances 0.000 abstract description 15
- 208000001914 Fragile X syndrome Diseases 0.000 abstract description 13
- 108091081062 Repeated sequence (DNA) Proteins 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 4
- 239000013615 primer Substances 0.000 description 160
- 239000000203 mixture Substances 0.000 description 37
- 108091034117 Oligonucleotide Proteins 0.000 description 33
- 102000004190 Enzymes Human genes 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 30
- 238000003556 assay Methods 0.000 description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- 108091093088 Amplicon Proteins 0.000 description 26
- 238000012360 testing method Methods 0.000 description 24
- 230000029087 digestion Effects 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 21
- 230000000295 complement effect Effects 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 238000001976 enzyme digestion Methods 0.000 description 18
- 238000012408 PCR amplification Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 238000010791 quenching Methods 0.000 description 16
- 230000000171 quenching effect Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 102100034343 Integrase Human genes 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000003155 DNA primer Substances 0.000 description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 9
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 8
- -1 bone marrow Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 7
- 206010003591 Ataxia Diseases 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 108010006785 Taq Polymerase Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 6
- 241000713838 Avian myeloblastosis virus Species 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 208000036626 Mental retardation Diseases 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 238000007834 ligase chain reaction Methods 0.000 description 5
- 238000007403 mPCR Methods 0.000 description 5
- 239000002751 oligonucleotide probe Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020005029 5' Flanking Region Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 208000024412 Friedreich ataxia Diseases 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 108010010677 Phosphodiesterase I Proteins 0.000 description 3
- 108010066717 Q beta Replicase Proteins 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 239000008051 TBE buffer Substances 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- ZWONWYNZSWOYQC-UHFFFAOYSA-N 5-benzamido-3-[[5-[[4-chloro-6-(4-sulfoanilino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OC1=C(N=NC2=CC(NC3=NC(NC4=CC=C(C=C4)S(O)(=O)=O)=NC(Cl)=N3)=CC=C2S(O)(=O)=O)C(=CC2=C1C(NC(=O)C1=CC=CC=C1)=CC(=C2)S(O)(=O)=O)S(O)(=O)=O ZWONWYNZSWOYQC-UHFFFAOYSA-N 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 101150029409 CFTR gene Proteins 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 206010027374 Mental impairment Diseases 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 101150067826 USP41 gene Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003274 myotonic effect Effects 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 238000007826 nucleic acid assay Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- RUDINRUXCKIXAJ-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptacosafluorotetradecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RUDINRUXCKIXAJ-UHFFFAOYSA-N 0.000 description 1
- KKYGNVFWTKCLOD-UHFFFAOYSA-N 2-aminobenzamide;1-(4-anilinonaphthalen-1-yl)pyrrole-2,5-dione Chemical compound NC(=O)C1=CC=CC=C1N.O=C1C=CC(=O)N1C(C1=CC=CC=C11)=CC=C1NC1=CC=CC=C1 KKYGNVFWTKCLOD-UHFFFAOYSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWZKAVBSQAVFI-UHFFFAOYSA-N 4-[(4-isothiocyanatophenyl)diazenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N=C=S)C=C1 OSWZKAVBSQAVFI-UHFFFAOYSA-N 0.000 description 1
- QXYRRCOJHNZVDJ-UHFFFAOYSA-N 4-pyren-1-ylbutanoic acid Chemical compound C1=C2C(CCCC(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 QXYRRCOJHNZVDJ-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- UOOMDCIYBWIMAF-UHFFFAOYSA-N 5-acetamido-2-[2-(4-isothiocyanato-2-sulfophenyl)ethenyl]benzenesulfonic acid acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21.OS(=O)(=O)C1=CC(NC(=O)C)=CC=C1C=CC1=CC=C(N=C=S)C=C1S(O)(=O)=O UOOMDCIYBWIMAF-UHFFFAOYSA-N 0.000 description 1
- YERWMQJEYUIJBO-UHFFFAOYSA-N 5-chlorosulfonyl-2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]benzenesulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(Cl)(=O)=O)C=C1S([O-])(=O)=O YERWMQJEYUIJBO-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- TXSWURLNYUQATR-UHFFFAOYSA-N 6-amino-2-(3-ethenylsulfonylphenyl)-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1C1=CC=CC(S(=O)(=O)C=C)=C1 TXSWURLNYUQATR-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- JBNOVHJXQSHGRL-UHFFFAOYSA-N 7-amino-4-(trifluoromethyl)coumarin Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(N)=CC=C21 JBNOVHJXQSHGRL-UHFFFAOYSA-N 0.000 description 1
- OQOAJAWQNHBZQZ-UHFFFAOYSA-N 7-amino-4-methylchromen-2-one;chromen-2-one Chemical compound C1=CC=C2OC(=O)C=CC2=C1.C1=C(N)C=CC2=C1OC(=O)C=C2C OQOAJAWQNHBZQZ-UHFFFAOYSA-N 0.000 description 1
- SGAOZXGJGQEBHA-UHFFFAOYSA-N 82344-98-7 Chemical compound C1CCN2CCCC(C=C3C4(OC(C5=CC(=CC=C54)N=C=S)=O)C4=C5)=C2C1=C3OC4=C1CCCN2CCCC5=C12 SGAOZXGJGQEBHA-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000007325 Amelogenin Human genes 0.000 description 1
- 102100035029 Ataxin-1 Human genes 0.000 description 1
- 102000004321 Atrophin-1 Human genes 0.000 description 1
- 108090000806 Atrophin-1 Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014817 CACNA1A Human genes 0.000 description 1
- SIRLQPQLXGAOFL-UHFFFAOYSA-N CCCC(O)=O.c1cc2ccc3cccc4ccc(c1)c2c34.c1cc2ccc3cccc4ccc(c1)c2c34 Chemical compound CCCC(O)=O.c1cc2ccc3cccc4ccc(c1)c2c34.c1cc2ccc3cccc4ccc(c1)c2c34 SIRLQPQLXGAOFL-UHFFFAOYSA-N 0.000 description 1
- DMURTSHZVFWQOE-UHFFFAOYSA-N CN(C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)Cl)C.N(=C=S)C=1C=C(C(=CC1)C=CC=1C(=CC(=CC1)N=C=S)S(=O)(=O)O)S(=O)(=O)O.N(=C=S)C1=CC(C(C=C1)C=CC=1C(=CC(=CC1)N=C=S)S(=O)(=O)O)S(=O)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.NCCNCCN Chemical compound CN(C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)Cl)C.N(=C=S)C=1C=C(C(=CC1)C=CC=1C(=CC(=CC1)N=C=S)S(=O)(=O)O)S(=O)(=O)O.N(=C=S)C1=CC(C(C=C1)C=CC=1C(=CC(=CC1)N=C=S)S(=O)(=O)O)S(=O)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.NCCNCCN DMURTSHZVFWQOE-UHFFFAOYSA-N 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101900242680 Escherichia coli Ribonuclease H Proteins 0.000 description 1
- 101001094518 Escherichia coli Ribonuclease H Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 1
- 101000740224 Homo sapiens Protein SCAI Proteins 0.000 description 1
- 101000617808 Homo sapiens Synphilin-1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 101100013186 Mus musculus Fmr1 gene Proteins 0.000 description 1
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102100037197 Protein SCAI Human genes 0.000 description 1
- MTVVRWVOXZSVBW-UHFFFAOYSA-M QSY21 succinimidyl ester Chemical compound [Cl-].C1CN(S(=O)(=O)C=2C(=CC=CC=2)C2=C3C=CC(C=C3OC3=CC(=CC=C32)N2CC3=CC=CC=C3C2)=[N+]2CC3=CC=CC=C3C2)CCC1C(=O)ON1C(=O)CCC1=O MTVVRWVOXZSVBW-UHFFFAOYSA-M 0.000 description 1
- BDJDTKYGKHEMFF-UHFFFAOYSA-M QSY7 succinimidyl ester Chemical compound [Cl-].C=1C=C2C(C=3C(=CC=CC=3)S(=O)(=O)N3CCC(CC3)C(=O)ON3C(CCC3=O)=O)=C3C=C\C(=[N+](\C)C=4C=CC=CC=4)C=C3OC2=CC=1N(C)C1=CC=CC=C1 BDJDTKYGKHEMFF-UHFFFAOYSA-M 0.000 description 1
- PAOKYIAFAJVBKU-UHFFFAOYSA-N QSY9 succinimidyl ester Chemical compound [H+].[H+].[Cl-].C=1C=C2C(C=3C(=CC=CC=3)S(=O)(=O)N3CCC(CC3)C(=O)ON3C(CCC3=O)=O)=C3C=C\C(=[N+](\C)C=4C=CC(=CC=4)S([O-])(=O)=O)C=C3OC2=CC=1N(C)C1=CC=C(S([O-])(=O)=O)C=C1 PAOKYIAFAJVBKU-UHFFFAOYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000021332 Syndactyly type 2 Diseases 0.000 description 1
- 102100021997 Synphilin-1 Human genes 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 230000001944 accentuation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HWKWYIHLDFQPNF-UHFFFAOYSA-N acridine;isothiocyanic acid Chemical compound N=C=S.C1=CC=CC2=CC3=CC=CC=C3N=C21.C1=CC=CC2=CC3=CC=CC=C3N=C21 HWKWYIHLDFQPNF-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- BBEAQIROQSPTKN-UHFFFAOYSA-N antipyrene Natural products C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150062912 cct3 gene Proteins 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- KPBGWWXVWRSIAY-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-6-isothiocyanato-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=C(N=C=S)C=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 KPBGWWXVWRSIAY-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- XHXYXYGSUXANME-UHFFFAOYSA-N eosin 5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 XHXYXYGSUXANME-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000023428 female meiosis Effects 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- AFAIELJLZYUNPW-UHFFFAOYSA-N pararosaniline free base Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=N)C=C1 AFAIELJLZYUNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000002957 synpolydactyly Diseases 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Optical Measuring Cells (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/544,293 US8163480B2 (en) | 2006-10-05 | 2006-10-05 | Nucleic acid size detection method |
US11/544,293 | 2006-10-05 | ||
PCT/US2007/008985 WO2008045136A2 (fr) | 2006-10-05 | 2007-04-11 | Procédé de détection de la dimension d'un acide nucléique |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2665723A1 true CA2665723A1 (fr) | 2008-04-17 |
Family
ID=39283328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002665723A Abandoned CA2665723A1 (fr) | 2006-10-05 | 2007-04-11 | Procede de detection de la dimension d'un acide nucleique |
Country Status (10)
Country | Link |
---|---|
US (2) | US8163480B2 (fr) |
EP (1) | EP2082055B1 (fr) |
JP (1) | JP5386357B2 (fr) |
CN (1) | CN101595227A (fr) |
AT (1) | ATE515573T1 (fr) |
AU (1) | AU2007307320B2 (fr) |
BR (1) | BRPI0720549A2 (fr) |
CA (1) | CA2665723A1 (fr) |
MX (1) | MX2009003736A (fr) |
WO (1) | WO2008045136A2 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8163480B2 (en) * | 2006-10-05 | 2012-04-24 | Quest Diagnostics Investments Incorporated | Nucleic acid size detection method |
US20080176237A1 (en) * | 2006-12-07 | 2008-07-24 | Biocept, Inc. | Non-invasive prenatal genetic screen |
US8409805B2 (en) * | 2009-02-13 | 2013-04-02 | Asuragen, Inc. | Method of amplification of GC-rich DNA templates |
WO2010094061A1 (fr) * | 2009-02-17 | 2010-08-26 | Murdoch Childrens Research Institute | Dosage permettant de déterminer les profils épigénétiques des marqueurs d'allèles de l'x fragile |
WO2010110835A1 (fr) * | 2009-03-24 | 2010-09-30 | Asuragen, Inc. | Procédés pcr pour caractériser la région 5' non traduite des gènes fmr1 et fmr2 |
CN101871001B (zh) * | 2009-04-22 | 2013-09-25 | 中山大学达安基因股份有限公司 | 检测脆性x综合征的试剂盒 |
AU2010271196B2 (en) * | 2009-07-10 | 2015-07-16 | Perkinelmer Health Sciences, Inc. | Detecting multinucleotide repeats |
US9382586B2 (en) | 2010-02-05 | 2016-07-05 | Quest Diagnostics Investments Incorporated | Method to detect repeat sequence motifs in nucleic acid |
AU2011288917B2 (en) | 2010-08-11 | 2015-01-22 | Murdoch Childrens Research Institute | Treatment and diagnosis of epigenetic disorders and conditions |
US20130316339A1 (en) * | 2010-09-01 | 2013-11-28 | Orion Genomics Llc | Detection of nucleic acid sequences adjacent to repeated sequences |
EP2707486B1 (fr) * | 2011-04-08 | 2020-06-10 | Zain-Luqman, Rula | Diagnostic et traitement de l'ataxie de friedreich |
US9863004B2 (en) | 2011-11-04 | 2018-01-09 | Gen-Probe Incorporated | Molecular assay reagents and methods |
US9371560B2 (en) | 2012-07-20 | 2016-06-21 | Asuragen, Inc. | Comprehensive FMR1 genotyping |
EP2732815A1 (fr) * | 2012-11-16 | 2014-05-21 | Neurochlore | Modulateurs de la concentration de chlorure intracellulaire pour le traitement du syndrome X fragile |
GB201301164D0 (en) * | 2013-01-23 | 2013-03-06 | Medical Res Council | Methods for estimating the size of disease-associated polynucleotide repaet expansions in genes |
EP4324936A3 (fr) * | 2013-03-14 | 2024-05-15 | Quest Diagnostics Investments Incorporated | Procédé de détection de la fibrose kystique |
US9273349B2 (en) * | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
GB201418144D0 (en) * | 2014-10-14 | 2014-11-26 | Univ Cardiff | High throughput sequencing |
CN104816447B (zh) * | 2015-04-30 | 2017-03-08 | 青岛科技大学 | 一种行星齿轮式混炼装置 |
CN104862302B (zh) * | 2015-05-05 | 2020-12-15 | 华南师范大学 | 一种dna片段化的方法及实现该方法的装置 |
GB201511508D0 (en) | 2015-07-01 | 2015-08-12 | Ge Healthcare Bio Sciences Ab | Method for determining a size of biomolecules |
JP2019013206A (ja) * | 2017-07-11 | 2019-01-31 | 国立大学法人帯広畜産大学 | アゾール耐性アスペルギルス・フミガーツスの検出方法および検出キット |
CN110184344A (zh) * | 2019-06-28 | 2019-08-30 | 北京和合医学诊断技术股份有限公司 | 检测htt基因cag三核苷酸重复序列的方法及引物对 |
CN110923305B (zh) * | 2019-11-25 | 2023-12-29 | 广州市达瑞生物技术股份有限公司 | 一种适用于脆性X综合征southern blot印迹杂交检测的DNA分子量标准 |
MX2023002015A (es) | 2020-08-18 | 2023-04-11 | Enviro Metals Llc | Refinamiento metálico. |
CN115851915A (zh) * | 2022-12-13 | 2023-03-28 | 长沙金域医学检验实验室有限公司 | 检测遗传性共济失调致病基因的引物组及方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8606719D0 (en) | 1986-03-19 | 1986-04-23 | Lister Preventive Med | Genetic probes |
US5135717A (en) | 1986-12-24 | 1992-08-04 | British Technology Group Usa Inc. | Tetrabenztriazaporphyrin reagents and kits containing the same |
US5206137A (en) | 1988-09-08 | 1993-04-27 | Lifecodes Corporation | Compositions and methods useful for genetic analysis |
NL9001639A (nl) | 1990-07-19 | 1992-02-17 | Amc Amsterdam | Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen. |
US5714327A (en) | 1990-07-19 | 1998-02-03 | Kreatech Diagnostics | Platinum-containing compounds, methods for their preparation and applications thereof |
US5364759B2 (en) | 1991-01-31 | 1999-07-20 | Baylor College Medicine | Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats |
US5652099A (en) | 1992-02-12 | 1997-07-29 | Conrad; Michael J. | Probes comprising fluorescent nucleosides and uses thereof |
US5695933A (en) | 1993-05-28 | 1997-12-09 | Massachusetts Institute Of Technology | Direct detection of expanded nucleotide repeats in the human genome |
US5599666A (en) | 1994-03-28 | 1997-02-04 | Promega Corporation | Allelic ladders for short tandem repeat loci |
US6013444A (en) | 1997-09-18 | 2000-01-11 | Oligotrail, Llc | DNA bracketing locus compatible standards for electrophoresis |
US6238863B1 (en) | 1998-02-04 | 2001-05-29 | Promega Corporation | Materials and methods for indentifying and analyzing intermediate tandem repeat DNA markers |
US6074831A (en) | 1998-07-09 | 2000-06-13 | Agilent Technologies, Inc. | Partitioning of polymorphic DNAs |
EP1384022A4 (fr) | 2001-04-06 | 2004-08-04 | California Inst Of Techn | Amplification d'acide nucleique au moyen de dispositifs microfluidiques |
US7855053B2 (en) | 2006-07-19 | 2010-12-21 | The Regents Of The University Of California | Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region |
US8163480B2 (en) * | 2006-10-05 | 2012-04-24 | Quest Diagnostics Investments Incorporated | Nucleic acid size detection method |
-
2006
- 2006-10-05 US US11/544,293 patent/US8163480B2/en not_active Expired - Fee Related
-
2007
- 2007-04-11 MX MX2009003736A patent/MX2009003736A/es active IP Right Grant
- 2007-04-11 US US12/444,361 patent/US8697399B2/en active Active
- 2007-04-11 AT AT07755301T patent/ATE515573T1/de not_active IP Right Cessation
- 2007-04-11 BR BRPI0720549-0A patent/BRPI0720549A2/pt not_active IP Right Cessation
- 2007-04-11 CN CNA2007800451729A patent/CN101595227A/zh active Pending
- 2007-04-11 JP JP2009531370A patent/JP5386357B2/ja not_active Expired - Fee Related
- 2007-04-11 WO PCT/US2007/008985 patent/WO2008045136A2/fr active Application Filing
- 2007-04-11 AU AU2007307320A patent/AU2007307320B2/en not_active Ceased
- 2007-04-11 CA CA002665723A patent/CA2665723A1/fr not_active Abandoned
- 2007-04-11 EP EP07755301A patent/EP2082055B1/fr not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
CN101595227A (zh) | 2009-12-02 |
US8163480B2 (en) | 2012-04-24 |
US20080124709A1 (en) | 2008-05-29 |
BRPI0720549A2 (pt) | 2014-07-29 |
US20100167284A1 (en) | 2010-07-01 |
AU2007307320A1 (en) | 2008-04-17 |
JP5386357B2 (ja) | 2014-01-15 |
US8697399B2 (en) | 2014-04-15 |
WO2008045136A2 (fr) | 2008-04-17 |
WO2008045136A3 (fr) | 2008-12-11 |
MX2009003736A (es) | 2009-07-09 |
EP2082055B1 (fr) | 2011-07-06 |
AU2007307320B2 (en) | 2013-07-11 |
EP2082055A4 (fr) | 2010-02-17 |
ATE515573T1 (de) | 2011-07-15 |
EP2082055A2 (fr) | 2009-07-29 |
JP2010505413A (ja) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007307320B2 (en) | Nucleic acid size detection method | |
US10689694B2 (en) | Methods, compositions, and kits for detecting allelic variants | |
US11965212B2 (en) | Nucleic acid detection combining amplification with fragmentation | |
US20230265510A1 (en) | Method to detect repeat sequence motifs in nucleic acid | |
US9765390B2 (en) | Methods, compositions, and kits for rare allele detection | |
US20020098484A1 (en) | Method of analyzing single nucleotide polymorphisms using melting curve and restriction endonuclease digestion | |
US9365892B2 (en) | Screening method for trinucleotide repeat sequences | |
AU4085200A (en) | Methods and oligonucleotides for detecting nucleic acid sequence variations | |
US7262032B2 (en) | Allele-specific mutation detection assay using an enzyme-disabling agent | |
WO2010135917A1 (fr) | Méthode de détection des variations dans des séquences d'acide nucléique | |
EP1633888A2 (fr) | Moyens et procede de detection de sequences nucleotidiques cibles, utilisant des melanges de ligation avec des paires de sondes oligonucleotidiques | |
US20110287424A1 (en) | Methylation-specific competitive allele-specific taqman polymerase chain reaction (cast-pcr) | |
WO2001062952A9 (fr) | Procedes de determination de variations uniques de nucleotides | |
US20070122818A1 (en) | Gene methylation assay controls | |
US20050053957A1 (en) | Polynucleotide sequence detection assays | |
US20060183136A1 (en) | Method for haplotyping and genotyping by melting curve analysis of hybridization probes | |
EP1400597A1 (fr) | Oligonucléotides pour l'amplification et la détection du gène de l'hémochromatose | |
JP2002223761A (ja) | 標的核酸検出法およびそのための試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20160413 |